Topic: checkpoint inhibitors
After watching from the sidelines as its rivals dove into I-O’s most coveted market, AstraZeneca finally has a win in previously untreated NSCLC.
It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.
Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.
Merck and Eisai are out with the expanded data that recently snagged their Keytruda-Lenvima combo three endometrial cancer go-aheads.
Merck’s Keytruda may have come up short in metastatic TNBC over the weekend, but in the pre-surgery setting, it posted a first-of its-kind win.
Merck won’t be stepping on Roche’s toes anytime soon in metastatic TNBC. But the New Jersey drugmaker says it learned from its phase 3 miss.
Right now, Merck’s Keytruda is the only I-O treatment approved solo in previously untreated NSCLC. But Roche’s Tecentriq is looking to make it two.
Roche has been looking to capture lung cancer share from Merck with its chemo combo. And it's trying to bring its quest to the monotherapy arena, too.
Roche was hoping Tecentriq could put up life-lengthening numbers in squamous NSCLC that could help it compete with Merck’s Keytruda—but no dice.
Merck’s Keytruda-chemo combo has a history of silencing its critics. And it may have just done it again.